Skip to main content
XORTX Therapeutics Inc. logo

XORTX Therapeutics Inc. — Investor Relations & Filings

Ticker · XRTX ISIN · CA98420Q2071 LEI · 254900RAT3XZPF9F9350 US Manufacturing
Open in API
Filings indexed 263 across all filing types
Latest filing 2024-09-12 Regulatory Filings
Country CA Canada
Listing US XRTX

About XORTX Therapeutics Inc.

https://www.xortx.com/

XORTX Therapeutics Inc. is a late-stage clinical biopharmaceutical company that develops and commercializes therapies for diseases associated with aberrant purine metabolism and high serum uric acid. The company's pipeline focuses on progressive kidney diseases, including Autosomal Dominant Polycystic Kidney Disease (ADPKD), Type 2 Diabetic Nephropathy (T2DN), and Acute Kidney Injury (AKI), as well as gout. Its lead program, XRx-008, is in development for the treatment of ADPKD.

Recent filings

Filing Released Lang Actions
FORM 6-K/A
Regulatory Filings Classification · 95% confidence The document is a Form 6-K/A, an amendment report filed by a foreign private issuer under the SEC rules. It includes an amended Management Discussion and Analysis (MD&A) for the three months ended June 30, 2024, along with CEO and CFO certificates. The total document length is only 1172 characters, which is quite short and primarily references exhibits and certifications rather than containing substantive financial data or full reports. According to the rules, certifications and attestations, even if referencing MD&A or financial periods, should be classified as Regulatory Filings (RNS). Also, the document is an amendment filing and does not contain the full MD&A report itself but references it as an exhibit. Therefore, the appropriate classification is Regulatory Filings (RNS).
2024-09-12 English
FORM 6-K/A
Regulatory Filings Classification · 95% confidence The document is a Form 6-K/A, an amendment report filed by a foreign private issuer under the Securities Exchange Act of 1934. It includes an amended Management Discussion and Analysis (MDA) for the year ended December 31, 2023, along with CEO and CFO certificates. The document length is only 1168 characters, indicating it is a short filing primarily containing amendments and certifications rather than the full MDA report itself. According to the rules, certifications and short amendment filings should be classified as Regulatory Filings (RNS), not as the full Management Reports (MDA). Therefore, the appropriate classification is Regulatory Filings (RNS).
2024-09-12 English
FORM 6-K
Regulatory Filings Classification · 95% confidence The document is a Form 6-K filed by a foreign private issuer, XORTX Therapeutics Inc., with the SEC. It includes a press release dated September 6, 2024, attached as Exhibit 99.1. The text indicates this is a regulatory filing to furnish a report or document under the rules applicable to foreign private issuers. The document length is 2672 characters, which is relatively short and primarily serves to submit the press release rather than containing detailed financial data or comprehensive reports. There is no substantive financial data, management discussion, or detailed report content. Therefore, this filing is best classified as a Regulatory Filing (RNS), which is the fallback category for miscellaneous filings that do not fit other specific categories and often includes Form 6-K submissions with press releases or other updates.
2024-09-06 English
FORM 6-K
Regulatory Filings Classification · 95% confidence The document is a Form 6-K, which is a report of a foreign private issuer filed with the SEC under the Securities Exchange Act of 1934. It includes a press release as an exhibit but does not contain detailed financial statements or substantive financial data. The document length is short (1237 characters), and it primarily serves as a regulatory filing to disclose a press release. According to the rules, such filings that do not contain full reports or detailed financial data should be classified as Regulatory Filings (RNS).
2024-09-03 English
FORM 6-K
Regulatory Filings Classification · 95% confidence The document is a Form 6-K filing, which is a report of a foreign private issuer submitted pursuant to SEC rules under the Securities Exchange Act of 1934. It includes a signature from the CEO and references an attached press release (Exhibit 99.1). The document length is short (1226 characters), and it primarily serves as a regulatory announcement of a press release rather than containing detailed financial data or substantive report content. Form 6-K filings typically serve as regulatory filings for miscellaneous updates by foreign issuers. Therefore, this document fits best under the Regulatory Filings (RNS) category as it does not contain a full report or detailed financial statements but is a formal regulatory submission with an attached press release.
2024-08-29 English
FORM 6-K
Regulatory Filings Classification · 95% confidence The document is a Form 6-K, which is a report of a foreign private issuer filed with the SEC. It includes a press release as an exhibit but does not contain detailed financial statements or substantive financial data. The document length is short (1226 characters), and it primarily serves as a regulatory filing to report current information, including the press release. According to the rules, such filings that do not contain full reports or detailed financial data should be classified as Regulatory Filings (RNS).
2024-08-23 English

Browse filings by year

7 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.